[A retrospective analysis of clinicopathological features and efficacy in 51 patients with high-grade B-cell lymphoma with 11q abnormalities].
In a retrospective cohort of 51 patients aged 5–84 years with HGBCL-11q, rituximab-containing high-intensity chemotherapy was associated with a higher complete response rate and longer progression-free survival than non-high-intensity treatment, alongside a distinctive germinal-center phenotype and recurrent genomic alterations.
Open original publication →What the AI sees
In a retrospective cohort of 51 patients aged 5–84 years with HGBCL-11q, rituximab-containing high-intensity chemotherapy was associated with a higher complete response rate and longer progression-free survival than non-high-intensity treatment, alongside a distinctive germinal-center phenotype and recurrent genomic alterations.
Research significance
The reported evidence supports an association between rituximab-containing high-intensity chemotherapy and improved response and progression-free survival in HGBCL-11q; it remains an inference, requiring prospective and age-specific validation, that treatment intensification improves outcomes—particularly in pediatric patients—without unacceptable toxicity.
Source abstract
To investigate the clinicopathological features, molecular genetic characteristics, and efficacy of chemotherapy regimens with different intensities in high-grade B-cell lymphoma with aberrations in the long arm of chromosome 11 (HGBCL-11q), this study retrospectively analyzed the data of 51 patients with HGBCL-11q at Henan Cancer Hospital, summarized their clinical, pathological and molecular profiles, and compared the differences in therapeutic efficacy and survival outcomes between groups with different treatment intensities. The median age of the 51 patients was 52 (5 - 84) years, with a male-to-female ratio of 1.22:1, and the digestive system was the most common site of involvement (18/51, 35.3% ). The tumor cells exhibited a germinal center B-cell immunophenotype: 47 patients (92.2% ) showed variable c-Myc expression in tumor cells (the proportion of positive cells ranged from 20% to 85% ), 41 patients (80.4% ) were negative for Bcl-2 expression, and 47 patients (92.2% ) had a Ki-67 proliferation index ≥90%. Fluorescence in situ hybridization confirmed the absence of MYC gene rearrangement and the presence of characteristic aberrations in 11q; recurrently mutated genes included DDX3X (60.0%, 12/20), PCLO (50.0%, 10/20), TP53 (45.0%, 9/20) and GNA13 (40.0%, 8/20), et al. The complete response rate in the rituximab-containing high-intensity chemotherapy group was significantly higher than that in the non-high-intensity group [87.5% (21/24) vs 60.9% (14/23), P=0.036], with longer progression-free survival [ (62.7±3.9) months vs (41.7±6.5) months, P=0.014]. In conclusion, HGBCL-11q has distinctive clinicopathological manifestations and molecular genetic features, and rituximab-containing high-intensity chemotherapy can significantly improve the response rate and survival of patients.